Which? Tells Government To Scrap Cosmetic Laser Deregulation, UK
As the Government's consultation* on the deregulation of cosmetic laser treatments closes, Jenny Driscoll, Campaigns Project Manager, Which? says:"The Government's current proposal to deregulate cosmetic laser treatments is at best ill-informed, and at worst a cold-hearted attempt to cut costs at the expense of people's health.
Morria Biopharmaceuticals Plc Announces Regulatory Approval To Commence Phase II Clinical Study Of MRX-4 In Allergic Rhinitis
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis (AR).
Pharmacy Has Key Role To Play In Reducing Health Inequalities, UK
Responding to the launch of the document Health Inequalities: Progress and Next Steps, by Health Secretary Alan Johnson on 9 June, the Royal Pharmaceutical Society of Great Britain (RPSGB) said that pharmacists are ideally placed to play a significant role in helping to reduce health inequalities across Britain.
Brittle Bones Drug And Breast Cancer
"A drug prescribed to combat brittle bones has been shown to prevent invasive breast cancer", The Times reported. The newspaper said a study has found that raloxifene - a drug used to prevent and treat osteoporosis - reduces the risk of developing invasive breast cancers by more than 50%.
Duska Therapeutics Licenses Portfolio Of Heart Failure Drugs From Duke And Johns Hopkins
Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska" or the "Company"), announced that it has been granted an exclusive, worldwide license from Duke University and Johns Hopkins University to develop and commercialize their rights to a portfolio of investigational cardiovascular drugs for the treatment of heart failure.
CuraGen Announces Expansion Of CR011-vcMMAE Phase II Trial In Melanoma
CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced that its Phase II Trial evaluating CR011-vcMMAE for the treatment of patients with unresectable Stage III or Stage IV melanoma has met the efficacy criteria for advancement to the second stage of enrollment.
Cancer Antibodies: Competitive Positioning For Success, Added To Research And Markets Report Offerings
Research and Markets has announced the addition of the "Cancer Antibodies: Competitive Positioning for Success""Cancer Antibodies: Competitive Positioning for Success" report to their offering. This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates.
Comparison Of 14, 18 And 20 Gauge Needles In Ex-Vivo Renal Mass Biopsy: A Prospective Blinded Study
ORLANDO, FL (UroToday.com) - As the diagnosis of small renal masses increases due to the widespread use of abdominal CT imaging, renal biopsies to determine the significance of these renal masses will also increase.
U.S. Medical Devices Industry Poised For A Healthy Growth
The Business & Financial Services practice at Frost & Sullivan is pleased to announce its 2008 Quarterly Analyst Briefing Presentation on the U.S. medical devices industry to be held on Tuesday, June 17, 2008 at 12:00 p.m. PDT. The underlying fundamentals of the U.
Hong Kong Culls Market Chickens After Finding More H5N1 Bird Flu
Health officials in Hong Kong said yesterday, Wednesday 11th June, they would start culling all live chickens on sale in retail outlets and markets after more birds in four markets tested positive for the deadly H5N1 virus that is also lethal to humans.